Status:
COMPLETED
Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-dens...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- High risk patients
- High doses of other statins
- LDL-C known, starts with Crestor 10 mg
- Permission to use patient data by AstraZeneca (AZ)
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
2650 Patients enrolled
Trial Details
Trial ID
NCT00240344
Start Date
September 1 2004
End Date
February 1 2008
Last Update
August 30 2011
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
's-Hertogenbosch, Netherlands
2
Research Site
Alkmaar, Netherlands
3
Research Site
Almelo, Netherlands
4
Research Site
Alphen aan den Rijn, Netherlands